A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...